StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) stock

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)

Close on Nov 17, 2026Market cap $4.82BP/E –Yield –

Travere Therapeutics cash

Cash and short-term investments held at the end of each period.

Travere Therapeutics's cash was $293.65M at Jun 30, 2026. For fiscal 2026 it was $238.42M, up 307.3% from the year before. Over ten years it grew 20.2% a year on average. The highest annual figure on record is $427.94M in fiscal 2022.

Annual cash

PeriodPeriod endValueChange
FY2026Dec 31, 2025$238.42M+307.3%
FY2025Dec 31, 2024$58.54M-80.9%
FY2024Dec 31, 2023$306.81M-11.6%
FY2023Dec 31, 2022$347.21M-18.9%
FY2022Dec 31, 2021$427.94M+20.0%
FY2021Dec 31, 2020$356.57M+31.1%
FY2020Dec 31, 2019$271.93M-12.7%
FY2019Dec 31, 2018$311.35M+39.8%
FY2018Dec 31, 2017$222.67M+443.1%
FY2017Dec 31, 2016$41.00M+8.5%
FY2016Dec 31, 2015$37.81M+107.7%
FY2015Dec 31, 2014$18.20M+203.6%
FY2014Dec 31, 2013$6.00M+153315.2%
FY2012Feb 29, 2012$3.91K–
FY2011Feb 28, 2011$0-100.0%
FY2010Feb 28, 2010$4.65K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2027Jun 30, 2026$293.65M+290.7%
Q1 FY2027Mar 31, 2026$208.95M+237.6%
Q4 FY2026Dec 31, 2025$238.42M+307.3%
Q3 FY2026Sep 30, 2025$249.59M-2.3%
Q2 FY2026Jun 30, 2025$75.15M-70.4%
Q1 FY2026Mar 31, 2025$61.90M-78.3%
Q4 FY2025Dec 31, 2024$58.54M-80.9%
Q3 FY2025Sep 30, 2024$255.36M-28.4%
Q2 FY2025Jun 30, 2024$253.94M-15.9%
Q1 FY2025Mar 31, 2024$284.61M-35.4%
Q4 FY2024Dec 31, 2023$306.81M-11.6%
Q3 FY2024Sep 30, 2023$356.87M-20.4%
Q2 FY2024Jun 30, 2023$301.98M-40.6%
Q1 FY2024Mar 31, 2023$440.43M-16.8%
Q4 FY2023Dec 31, 2022$347.21M-18.9%
Q3 FY2023Sep 30, 2022$448.09M-1.0%
Q2 FY2023Jun 30, 2022$508.78M+23.6%
Q1 FY2023Mar 31, 2022$529.67M+22.9%
Q4 FY2022Dec 31, 2021$427.94M+20.0%
Q3 FY2022Sep 30, 2021$452.79M+13.4%
Q2 FY2022Jun 30, 2021$411.54M+11.1%
Q1 FY2022Mar 31, 2021$431.01M+59.7%
Q4 FY2021Dec 31, 2020$356.57M+31.1%
Q3 FY2021Sep 30, 2020$399.27M+34.8%
Q2 FY2021Jun 30, 2020$370.29M+24.1%
Q1 FY2021Mar 31, 2020$269.87M-0.3%
Q4 FY2020Dec 31, 2019$271.93M-12.7%
Q3 FY2020Sep 30, 2019$296.10M-15.6%
Q2 FY2020Jun 30, 2019$298.37M+234.1%
Q1 FY2020Mar 31, 2019$270.67M+342.9%
Q4 FY2019Dec 31, 2018$311.35M+39.8%
Q3 FY2019Sep 30, 2018$350.88M+254.5%
Q2 FY2019Jun 30, 2018$89.31M+0.0%
Q1 FY2019Mar 31, 2018$61.12M+46.0%
Q4 FY2018Dec 31, 2017$222.67M+443.1%
Q3 FY2018Sep 30, 2017$98.99M+314.3%
Q2 FY2018Jun 30, 2017$89.27M–
Q1 FY2018Mar 31, 2017$41.87M–
Q4 FY2017Dec 31, 2016$41.00M–
Q3 FY2017Sep 30, 2016$23.90M–

More Travere Therapeutics figures

See a number that looks wrong?